Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Soligenix, Inc. (SNGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its 10-K and 10-Q reports, 8-K current reports and registration statements such as Form S-1. Soligenix describes itself in these documents as a Delaware-incorporated, late-stage biopharmaceutical company listed on The Nasdaq Capital Market, focused on rare-disease therapeutics and biodefense-oriented vaccines through its Specialized BioTherapeutics and Public Health Solutions segments.
For this issuer, Form 10-K and Form 10-Q are central for understanding segment results, research and development spending, risk factors and details on programs like HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, dusquetide-based candidates SGX942 and SGX945, and vaccine initiatives such as RiVax®, filovirus vaccines and CiVax™ leveraging the ThermoVax® platform. These periodic reports also describe government grant and contract funding from agencies including NIAID, DTRA and BARDA that support the Public Health Solutions segment.
Form 8-K current reports are particularly relevant for SNGX because they capture material events such as clinical milestones, FDA orphan drug designations, equity offerings and Nasdaq listing status updates. For example, 8-K filings in 2025 document an orphan drug designation for dusquetide in Behçet's Disease, a Nasdaq notice regarding stockholders’ equity compliance and a subsequent notice of regained compliance, the approval of a 2025 equity incentive plan, and the closing of a public offering that extended the company’s cash runway.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new financing terms, changes in capital structure, or updates to clinical and regulatory strategy. Users can also track insider transaction reports on Form 4, along with registration statements like Form S-1 related to public offerings and warrant issuances, to better understand dilution, capital-raising activities and governance matters for Soligenix.
Soligenix, Inc. has entered into an at-the-market equity sales agreement with Rodman & Renshaw, LLC, allowing the company to sell shares of its common stock from time to time with an aggregate offering price of up to $3,450,000. Sales, if any, will be made through Rodman as sales agent on The Nasdaq Capital Market or other U.S. trading markets, at market-related or negotiated prices, as defined in Rule 415 under the Securities Act.
The company will control key parameters for each sales period, such as the number of shares sold, time window, daily volume limits, and any minimum price. Soligenix is not obligated to sell any shares, may suspend solicitations, and either party may terminate the agreement under specified conditions, with the program ending no later than December 15, 2026 unless ended earlier. Rodman will receive a commission of up to 3.0% of gross proceeds, and shares will be issued under Soligenix’s effective Form S-3 shelf registration statement and a related prospectus supplement.
Soligenix consulting chief medical officer Richard Straube reported an equity award in the form of stock options. On December 11, 2025, he received options to acquire 10,000 shares of Soligenix common stock at an exercise price of $1.63 per share, expiring on December 10, 2035.
According to the filing, the option vested immediately as to 25% of the shares, with the remaining 75% vesting in 12 installments (or nearly equal installments) on each three‑month anniversary of December 11, 2025. The filing shows 10,000 derivative securities beneficially owned directly following this transaction.
Soligenix, Inc. reported an insider equity award to its chief scientific officer. On December 11, 2025, the officer received a stock option covering 100,000 shares of Soligenix common stock at an exercise price of $1.63 per share.
The option expires on December 10, 2035. According to the disclosure, 25% of the option vested immediately on December 11, 2025, and the remaining 75% will vest in 12 approximately equal installments on each three-month anniversary of that date.
Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino. He received a stock option grant covering 100,000 options to purchase common stock at an exercise price of $ 1.63 per share on December 11, 2025.
The option expires on December 10, 2035. It vested immediately as to 25% of the shares, with the remaining 75% scheduled to vest in 12 equal installments on each three month anniversary of December 11, 2025. Following this grant, he beneficially owns 100,000 derivative securities directly.
Soligenix, Inc. reported that its Chairman, CEO and President Christopher J. Schaber received a stock option grant covering 200,000 shares of common stock on December 11, 2025, with an exercise price of $1.63 per share and an expiration date of December 10, 2035. The option vests 25% immediately, with the remaining 75% vesting in 12 equal installments on each three-month anniversary of December 11, 2025.
Soligenix, Inc. reports that it has regained compliance with Nasdaq’s minimum stockholders’ equity listing standard. Nasdaq requires at least $2,500,000 of stockholders’ equity for companies on The Nasdaq Capital Market. In its Quarterly Report for the quarter ended September 30, 2025, Soligenix reported stockholders’ equity of $7,597,976, which exceeded this requirement. On November 18, 2025, Nasdaq sent a letter confirming the company is again in compliance and that the listing matter is closed.
Soligenix, Inc. filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the offer and sale by the company of 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
In the 10‑Q, Soligenix reported cash and cash equivalents of $10,525,335 and stockholders’ equity of $7,597,976 as of September 30, 2025. The company recorded a net loss of $2,530,947 for Q3 2025 and $8,184,191 for the nine months ended September 30, 2025. The filing notes a completed September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.
Soligenix also disclosed it received a Nasdaq notice on August 15, 2025 regarding minimum stockholders’ equity, and believes it has since regained compliance. Shares outstanding were 10,086,130 as of October 31, 2025.
Soligenix filed a prospectus supplement registering 4,253 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
Cash and cash equivalents were $10,525,335, and stockholders’ equity was $7,597,976 as of September 30, 2025. The company reported a net loss of $2,530,947 for the quarter. As of October 31, 2025, 10,086,130 shares were outstanding.
Soligenix noted it had received an August 2025 Nasdaq notice regarding the equity listing standard and believes it has regained compliance following a September 29, 2025 public offering with approximately $7.5 million in gross proceeds.
Soligenix (SNGX) filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the resale of up to 1,054,688 shares of common stock issuable upon exercise of previously issued common warrants by selling stockholders. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
As of October 31, 2025, shares outstanding were 10,086,130. For Q3 2025, the company reported a net loss of $2,530,947, and for the nine months year‑to‑date a net loss of $8,184,191. Cash and cash equivalents were $10,525,335 as of September 30, 2025, and stockholders’ equity totaled $7,597,976.
Management noted it received a Nasdaq notice on August 15, 2025 for stockholders’ equity non‑compliance and believes it regained compliance following a September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.
Soligenix filed its Q3 2025 10‑Q, reporting a smaller quarterly net loss and strengthened equity from recent financings. The company posted a net loss of $2,530,947 for the quarter and $8,184,191 year‑to‑date, with no 2025 revenue as it advances late‑stage programs. Research and development expense was $1,583,879 in the quarter and $5,202,573 year‑to‑date; general and administrative was $996,604 and $3,168,297, respectively.
Liquidity improved: cash and cash equivalents were $10,525,335, and stockholders’ equity rose to $7,597,976. The company completed a public offering on September 29, 2025 with total gross proceeds of approximately $7.5 million and executed ATM sales totaling $4,666,421 year‑to‑date. Convertible debt was fully repaid in February 2025.
Management states resources are sufficient for at least the next twelve months. Nasdaq notified the company in August about equity compliance; Soligenix believes it has regained compliance, supported by the September offering. The FLASH2 Phase 3 CTCL study is enrolling, with top‑line results anticipated in the second half of 2026.